Anamarija Kruljac‐Letunic
Eli Lilly (Germany) · 7 works · 683 citations · h-index 5
Top works
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- The Tyrosine Kinase Pyk2 Regulates Arf1 Activity by Phosphorylation and Inhibition of the Arf-GTPase-activating Protein ASAP1
- A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
- The C-terminal Tail of CRTH2 Is a Key Molecular Determinant That Constrains Gαi and Downstream Signaling Cascade Activation
- XMAP215–EB1 Interaction Is Required for Proper Spindle Assembly and Chromosome Segregation in Xenopus Egg Extract
- Assay and Functional Properties of the Tyrosine Kinase Pyk2 in Regulation of Arf1 Through ASAP1 Phosphorylation
- Chromatography